| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Mesoblast Limited (NASDAQ: MESO)
MESO Technical Analysis
5
| As on 20th Jun 2025 MESO SHARE Price closed @ 10.44 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 6.03 & Strong Buy for SHORT-TERM with Stoploss of 1.83 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MESOSHARE Price
| Open | 11.00 | Change | Price | % |
| High | 11.06 | 1 Day | -1.25 | -10.69 |
| Low | 10.41 | 1 Week | -2.27 | -17.86 |
| Close | 10.44 | 1 Month | -0.61 | -5.52 |
| Volume | 437899 | 1 Year | 9.36 | 866.67 |
| 52 Week High 21.04 | 52 Week Low 1.04 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| HCTI | 0.03 | 0.00% |
| NVDA | 143.85 | -1.12% |
| GNLN | 0.01 | 0.00% |
| PCSA | 0.32 | 33.33% |
| INTC | 21.08 | -1.91% |
| LMDX | 0.02 | 0.00% |
| LCID | 2.19 | -1.35% |
| NCNA | 0.10 | -16.67% |
| TSLA | 322.16 | 0.03% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| MESO Daily Charts |
MESO Intraday Charts |
Whats New @ Bazaartrend |
MESO Free Analysis |
|
|
MESO Important Levels Intraday
| RESISTANCE | 11.69 |
| RESISTANCE | 11.29 |
| RESISTANCE | 11.04 |
| RESISTANCE | 10.79 |
| SUPPORT | 10.09 |
| SUPPORT | 9.84 |
| SUPPORT | 9.59 |
| SUPPORT | 9.19 |
MESO Forecast June 2025
| 4th UP Forecast | 13.21 |
| 3rd UP Forecast | 12.32 |
| 2nd UP Forecast | 11.77 |
| 1st UP Forecast | 11.22 |
| 1st DOWN Forecast | 9.66 |
| 2nd DOWN Forecast | 9.11 |
| 3rd DOWN Forecast | 8.56 |
| 4th DOWN Forecast | 7.67 |
MESO Weekly Forecast
| 4th UP Forecast | 12.39 |
| 3rd UP Forecast | 11.76 |
| 2nd UP Forecast | 11.38 |
| 1st UP Forecast | 10.99 |
| 1st DOWN Forecast | 9.89 |
| 2nd DOWN Forecast | 9.50 |
| 3rd DOWN Forecast | 9.12 |
| 4th DOWN Forecast | 8.49 |
MESO Forecast2025
| 4th UP Forecast | 50.91 |
| 3rd UP Forecast | 37.93 |
| 2nd UP Forecast | 29.91 |
| 1st UP Forecast | 21.89 |
| 1st DOWN Forecast | -1.01 |
| 2nd DOWN Forecast | -9.03 |
| 3rd DOWN Forecast | -17.05 |
| 4th DOWN Forecast | -30.03 |
Mesoblast Limited ( NASDAQ USA Symbol : MESO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MESO Business Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrĂ¼nenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Address: 55 Collins Street, Melbourne, VIC, Australia, 3000
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service